SCHEMBL4462811

SCHEMBL4462811

CCCCC1CNC(=O)OC12CCN(Cc1ccccc1)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.46
OPRK1 P41145 2/20 0.46
OPRL1 P41146 2/20 0.46
OPRD1 P41143 1/20 0.46
CCR5 P51681 4/20 0.44
SIGMAR1 Q99720 4/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
HSD11B1 P28845 2/20 0.42
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
LMNA P02545 1/20 0.41
CHRM2 P08172 1/20 0.41
ADRA2A P08913 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13864847 0.82 OPRL1 (0.48) OPRM1OPRK1OPRL1OPRD1SIGMAR1
SCHEMBL13617695 0.79 CCR5 (0.43) OPRM1OPRK1OPRL1OPRD1CCR5
SCHEMBL14136159 0.78 OPRL1 (0.47) OPRM1OPRK1OPRL1OPRD1SIGMAR1
SCHEMBL12527074 0.75 SIGMAR1 (0.42) OPRL1SIGMAR1ABL1RIN1CYP2D6
SCHEMBL4471178 0.74 CCR5 (0.59) CCR5
SCHEMBL17113644 0.74 OPRM1 (0.50) OPRM1OPRK1OPRL1OPRD1CCR5
SCHEMBL13873260 0.73 TSHR (0.51) OPRL1CCR5SIGMAR1ABL1RIN1
SCHEMBL3960811 0.71 CCR5 (0.43) OPRM1OPRK1OPRL1OPRD1CCR5
SCHEMBL3959286 0.71 CCR5 (0.43) OPRM1OPRK1OPRL1OPRD1CCR5
SCHEMBL13873258 0.71 CCR5 (0.43) OPRM1OPRK1OPRL1OPRD1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538122-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2009-05-26 US disclosed
US-7538122-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2009-05-26 US disclosed
US-20080139544-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2008-06-12 US disclosed
US-20080139544-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2008-06-12 US disclosed
US-7332500-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2008-02-19 US disclosed
US-7332500-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2008-02-19 US disclosed
EP-1716156-A2 CHEMOKINE CCR5 RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2006-11-02 EP disclosed
WO-2005075484-A2 CHEMOKINE CCR5 RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-08-18 WO disclosed
US-20050176703-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139544-A1 Heterocyclic antiviral compounds CCR5, CCR3, CCR1 OPRM1 35/4885OPRK1 33/4885OPRL1 53/4885
US-20050176703-A1 Heterocyclic antiviral compounds CCR5, CCR3, CCR1 OPRM1 35/4885OPRK1 33/4885OPRL1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.